• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Wedbush initiated coverage on Ikena Oncology with a new price target

    9/22/23 7:17:31 AM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IKNA alert in real time by email
    Wedbush initiated coverage of Ikena Oncology with a rating of Outperform and set a new price target of $11.00
    Get the next $IKNA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IKNA

    DatePrice TargetRatingAnalyst
    5/29/2024$8.00 → $2.00Outperform → Neutral
    Wedbush
    9/22/2023$11.00Outperform
    Wedbush
    5/4/2023$18.00Buy
    H.C. Wainwright
    12/23/2021$25.00Buy
    HC Wainwright & Co.
    8/13/2021$30.00 → $27.00Outperform
    Credit Suisse
    More analyst ratings

    $IKNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wooster Richard

      4 - Ikena Oncology, Inc. (0001835579) (Issuer)

      6/10/24 4:15:08 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Dukes Iain D.

      4 - Ikena Oncology, Inc. (0001835579) (Issuer)

      6/10/24 4:15:06 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Formela Jean Francois

      4 - Ikena Oncology, Inc. (0001835579) (Issuer)

      6/10/24 4:15:09 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

      The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) --  Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflamma

      7/25/25 11:00:00 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

      BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

      7/23/25 9:00:00 AM ET
      $IKNA
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

      Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") today announced the results of the annual meeting of its stockholders held on July 15, 2025. At the annual meeting, Ikena's stockholders voted in favor of all proposals, including a proposal approving the previously announced merger with Inmagene Biopharmaceuticals ("Inmagene"). The merger proposal allows for the issuance of shares of Ikena's common stock both to the shareholders of Inmagene and to the investors of the financing concurrent to the merger. Following th

      7/15/25 4:15:00 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ikena Oncology downgraded by Wedbush with a new price target

      Wedbush downgraded Ikena Oncology from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously

      5/29/24 7:45:06 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Ikena Oncology with a new price target

      Wedbush initiated coverage of Ikena Oncology with a rating of Outperform and set a new price target of $11.00

      9/22/23 7:17:31 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright resumed coverage on Ikena Oncology with a new price target

      H.C. Wainwright resumed coverage of Ikena Oncology with a rating of Buy and set a new price target of $18.00

      5/4/23 8:00:07 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    SEC Filings

    See more
    • Ikena Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Ikena Oncology, Inc. (0001835579) (Filer)

      7/25/25 12:23:39 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Ikena Oncology Inc.

      10-Q - Ikena Oncology, Inc. (0001835579) (Filer)

      7/24/25 5:17:25 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Ikena Oncology Inc.

      8-K - Ikena Oncology, Inc. (0001835579) (Filer)

      7/24/25 9:18:39 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Financials

    Live finance-specific insights

    See more
    • Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

      Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena's acquisition of Pionyr in an all-stock transaction. Ikena acquired all of Pionyr's assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a com

      8/7/23 7:00:00 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

      BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.

      7/23/25 9:00:00 AM ET
      $IKNA
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ikena Oncology Reports Second Quarter 2024 Financial Results

      BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company"))) today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its ongoing activities. Pipeline Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety evaluation period Promising early pharmacokinetics (PK) and pharmacodynamics (PD) activity has been observed, with dose dependent exposure and target modulation measured in the blood In May 2024, the Company announced the discontinuation of the IK-930 clinical program Corporate Updates In

      8/8/24 4:15:00 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ikena Oncology Inc.

      SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)

      11/14/24 5:05:17 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ikena Oncology Inc.

      SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)

      11/13/24 4:05:14 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Ikena Oncology Inc. (Amendment)

      SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)

      3/11/24 8:19:04 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care